BeOne Medicines said on Wednesday that the ‌U.S. Food and Drug ‌Administration has approved its drug for ​a type of blood cancer.

U.S.-listed shares of the company were up more than 1% in ‌afternoon trade.

The ⁠drug, branded as Beqalzi, was greenlit to treat ⁠relapsed or refractory mantle cell lymphoma, an aggressive cancer of ​the lymphatic ​system, which ​contains disease-fighting white ‌blood cells, that relapses after initial treatment or fails to respond to it.

The regulator’s accelerated approval was based on a ‌early-to-mid stage study ​in which the ​drug ​showed a complete response, ‌or disappearance of all ​detectable ​signs of cancer, in 16% of the patients on the ​drug.